BMJ Clin Evid 2015[]; 2015 (ä): ä PMIDC4400653show ga
Introduction: Acute rhinosinusitis is defined pathologically by transient inflammation of the mucosal lining of the paranasal sinuses lasting less than 4 weeks. Clinically, it is characterised by nasal congestion, rhinorrhoea, facial pain, hyposmia, sneezing, and, if more severe, additional malaise and fever. It affects 1% to 5% of the adult population each year in Europe. Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments in people with clinically diagnosed acute rhinosinusitis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2013 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Results: We found 12 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (amoxicillin, amoxicillin-clavulanic acid [co-amoxiclav], doxycycline, cephalosporins, macrolides; long-course regimens), corticosteroids (intranasal), decongestants (xylometazoline, phenylephrine, pseudoephedrine), and saline nasal washes.
free
free
free
BMJ+Clin+Evid 2015 ; 2015 (ä): ä
